scholarly journals Preliminary Experience on Laser Interstitial Thermal Ablation Therapy in the Treatment of Extra-axial Masses: Indications, Imaging Characterization and Outcomes

Cureus ◽  
2018 ◽  
Author(s):  
Armando Ruiz ◽  
Roberto J Diaz ◽  
Simon Buttrick ◽  
Michael Ivan ◽  
Mehul Desai ◽  
...  
Keyword(s):  
Thermal Ablation ◽  
Ablation Therapy ◽  
Thermal Ablation Therapy ◽  
Imaging Characterization

scholarly journals Application of Nanoparticles and Nanomaterials in Thermal Ablation Therapy of Cancer

Nanomaterials ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. 1195 ◽  
Author(s):  
Zhannat Ashikbayeva ◽  
Daniele Tosi ◽  
Damir Balmassov ◽  
Emiliano Schena ◽  
Paola Saccomandi ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Thermal Ablation ◽  
Conventional Heating ◽  
Great Promise ◽  
Magnetic Iron Oxide Nanoparticles ◽  
Ablation Therapy ◽  
Treatment Techniques ◽  
Thermal Ablation Therapy ◽  
Heating Capacity ◽  
Tumor Region

Cancer is one of the major health issues with increasing incidence worldwide. In spite of the existing conventional cancer treatment techniques, the cases of cancer diagnosis and death rates are rising year by year. Thus, new approaches are required to advance the traditional ways of cancer therapy. Currently, nanomedicine, employing nanoparticles and nanocomposites, offers great promise and new opportunities to increase the efficacy of cancer treatment in combination with thermal therapy. Nanomaterials can generate and specifically enhance the heating capacity at the tumor region due to optical and magnetic properties. The mentioned unique properties of nanomaterials allow inducing the heat and destroying the cancerous cells. This paper provides an overview of the utilization of nanoparticles and nanomaterials such as magnetic iron oxide nanoparticles, nanorods, nanoshells, nanocomposites, carbon nanotubes, and other nanoparticles in the thermal ablation of tumors, demonstrating their advantages over the conventional heating methods.

scholarly journals SonoKnife: Feasibility of a line-focused ultrasound device for thermal ablation therapy

2011 ◽  
Vol 38 (7) ◽  
pp. 4372-4385 ◽  
Author(s):  
Duo Chen ◽  
Rongmin Xia ◽  
Xin Chen ◽  
Gal Shafirstein ◽  
Peter M. Corry ◽  
...  
Keyword(s):  
Thermal Ablation ◽  
Focused Ultrasound ◽  
Ablation Therapy ◽  
Ultrasound Device ◽  
Thermal Ablation Therapy

Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma

2021 ◽  
pp. 000313482110545
Author(s):  
Min Deng ◽  
Shao-Hua Li ◽  
Rong-Ping Guo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Liver Resection ◽  
Thermal Ablation ◽  
Good Choice ◽  
Local Tumor Recurrence ◽  
Ablation Therapy ◽  
First Line Therapy ◽  
Thermal Ablation Therapy ◽  
Arterial Chemoembolization

Image-guided local thermal ablation (LTA) plays an important role in the treatment of hepatocellular carcinoma (HCC), especially in patients with HCC who are not suitable for hepatectomy. Radiofrequency ablation (RFA) and microwave ablation (MWA) are the most widely used LTA clinically. Radiofrequency ablation can achieve the best result; that is, a similar therapeutic effect as hepatectomy if the tumor ≤3 cm, while MWA can effectively ablate tumors ≤5 cm. Local thermal ablation has an advantage over liver resection in terms of minimally invasive surgery and can achieve a comparable prognosis and efficacy to liver resection. For borderline liver function, selecting LTA as the first-line therapy may bring more benefits to patients with cirrhosis background. In addition, a combination of multiple therapies for HCC is a good choice, such as LTA combined with transcatheter arterial chemoembolization (TACE), which can achieve a better prognosis than single therapy for larger tumors. For patients who are awaiting liver transplantation, LTA is a good choice. The main problem of LTA needed to be solved is to prevent the local tumor recurrence after ablation in patients with HCC.

scholarly journals Molecular Enhancement of Thermal Ablation Therapies Using TNF-α-Coated Gold Nanoparticles in a Translational Model of Renal Tumors

2009 ◽  
Vol 3 (2) ◽  
Author(s):  
R. Pedro ◽  
K. Thekke-Adiyat ◽  
M. Shenoi ◽  
R. Goel ◽  
S. Schmechel ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Thermal Ablation ◽  
Tumor Model ◽  
Renal Tumors ◽  
Rabbit Kidney ◽  
Thermal Lesion ◽  
Ablation Therapy ◽  
Treatment Groups ◽  
Thermal Ablation Therapy ◽  
Tnf Α

Thermal ablation therapies are currently used for the treatment of select renal masses. Such treatments are limited to tumors that are small (<3 cm diameter), exophytic, and away from vital structures such as ureter or intestine. Novel treatment approaches are geared towards increasing the size of the thermal lesion created, limiting damage to collateral normal tissues, reducing local recurrence and distant metastases as well as improving the imaging potential of the therapy. Previous studies have demonstrated the enhancement of thermal therapies in pre-clinical murine models of solid tumors by intravenously infusing 33 nm TNF-α and PEG coated gold nanoparticles (CYT-6091, Cytimmune Sciences Inc.) prior to ablation. This study investigates the enhancement of thermal ablation therapy by CYT-6091 in a translational animal model of renal tumors. New Zealand White rabbits (37 for radiofrequency ablation (RFA), 20 for cryoablation) had VX-2 tumors implanted into their bilateral kidneys. The tumors were allowed to grow for 14 days to a size of ∼1 cm. For RFA, the rabbits were split into 3 treatment groups of 10 rabbits each and a sham group of 7 rabbits. The groups were treated with CYT-6091 (200 μg/kg) only, RFA only, or CYT-6091 (200 μg/kg) followed 4 hours later by RFA. For cryoablation, 2 treatment groups of 10 rabbits each were used. The groups were treated with cryoablation only or CYT-6091 (200 μg/kg) followed 4 hours later by cryoablation. The kidneys were harvested 3 days later for RFA and 7 days later for cryoablation. Gross and microscopic measurements of the ablation size as well as histological analysis using H&E staining were performed. The RFA plus CYT-6091 group had a larger zone of complete cell death than the RFA only group when measured both on gross sectioning (0.32±0.03 vs. 0.22±0.07cm3, p=0.015) and on microscopic examination (0.30±0.07 vs. 0.23±0.03cm3, p=0.03). Overall this was a 23% increase in ablation volume. This difference in ablation size was due to a replacement of partially ablated tissue at the periphery in the RFA only group by completely ablated tissue in the RFA plus CYT-6091 group. Thus this zone of partially ablated tissue was smaller in the RFA plus CYT-6091 group than the RFA only group (0.08±0.02cm3 vs. 0.13±0.05cm3, p=0.01). Excessive tumor growth into the ablation lesion at day 7 following cryoablation prevented accurate measurements in these groups; however, a significant decrease in the rate of peritoneal carcinomatosis (metastases) was obtained in the cryo plus CYT-6091 group compared to the cryoablation alone group (1/10 vs. 8/10, p=0.04). We have shown that use of CYT-6091 prior to thermal ablation therapy in a rabbit kidney tumor model can minimize the zone of partial treatment at the periphery of the thermal lesion and thus maximize the complete kill zone in RFA while significantly decreasing the rate of metastases in cryoablation. These data provide preliminary evidence for the efficacy of adjuvant use of CYT-6091 for thermal ablation therapies in a large animal translational tumor model.

Sign in / Sign up

Export Citation Format

Share Document